IL140721A0 - Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties - Google Patents

Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Info

Publication number
IL140721A0
IL140721A0 IL14072199A IL14072199A IL140721A0 IL 140721 A0 IL140721 A0 IL 140721A0 IL 14072199 A IL14072199 A IL 14072199A IL 14072199 A IL14072199 A IL 14072199A IL 140721 A0 IL140721 A0 IL 140721A0
Authority
IL
Israel
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
radiosensitizing properties
vivo
Prior art date
Application number
IL14072199A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL140721A0 publication Critical patent/IL140721A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14072199A 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties IL140721A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18
PCT/EP1999/004545 WO2000001411A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (1)

Publication Number Publication Date
IL140721A0 true IL140721A0 (en) 2002-02-10

Family

ID=26150503

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14072199A IL140721A0 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
IL140721A IL140721A (en) 1998-07-06 2001-01-04 Use of the Prenzil Transparase protein inhibitor for the preparation of a pharmaceutical preparation with properties that increase radiation sensitivity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL140721A IL140721A (en) 1998-07-06 2001-01-04 Use of the Prenzil Transparase protein inhibitor for the preparation of a pharmaceutical preparation with properties that increase radiation sensitivity

Country Status (31)

Country Link
US (1) US6545020B1 (tr)
EP (1) EP1094839B1 (tr)
JP (1) JP4530537B2 (tr)
KR (1) KR100591603B1 (tr)
CN (1) CN1152716C (tr)
AP (1) AP1599A (tr)
AT (1) ATE238811T1 (tr)
AU (1) AU762423B2 (tr)
BG (1) BG64941B1 (tr)
BR (1) BR9911861A (tr)
CA (1) CA2336624C (tr)
CZ (1) CZ300968B6 (tr)
DE (1) DE69907461T2 (tr)
DK (1) DK1094839T3 (tr)
EA (1) EA003877B1 (tr)
EE (1) EE04582B1 (tr)
ES (1) ES2199579T3 (tr)
HK (1) HK1034451A1 (tr)
HR (1) HRP20000903A2 (tr)
HU (1) HU229076B1 (tr)
ID (1) ID26987A (tr)
IL (2) IL140721A0 (tr)
MY (1) MY126519A (tr)
NO (1) NO328178B1 (tr)
PL (1) PL193464B1 (tr)
PT (1) PT1094839E (tr)
SI (1) SI1094839T1 (tr)
SK (1) SK284723B6 (tr)
TR (1) TR200003879T2 (tr)
TW (1) TW586937B (tr)
WO (1) WO2000001411A1 (tr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762423B2 (en) 1998-07-06 2003-06-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties
SI1094815T1 (en) 1998-07-06 2004-04-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
CA2396865C (en) * 2000-02-04 2009-04-14 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322650B1 (en) 2000-09-25 2008-09-24 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
ATE325116T1 (de) * 2000-12-27 2006-06-15 Janssen Pharmaceutica Nv Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
AU2003223970B2 (en) 2002-03-22 2008-03-06 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
EP1687277B1 (en) * 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005051392A1 (en) 2003-11-20 2005-06-09 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
JP2010528034A (ja) * 2007-05-23 2010-08-19 アラーガン、インコーポレイテッド 医薬としての((フェニル)イミダゾリル)メチルキノリニル化合物
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
ATE555384T1 (de) 2008-06-26 2012-05-15 Spherotec Gmbh Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
BR112015008308A2 (pt) 2012-10-16 2017-12-05 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por metileno do ror-gama-t
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ.ベー. Rorγtのアルキル結合キノリニルモジュレーター
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP3995589A1 (en) 2015-08-17 2022-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
CA3042747A1 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN109475550A (zh) 2017-02-21 2019-03-15 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
WO2019032489A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3873469A2 (en) 2018-11-01 2021-09-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2020254492A1 (en) 2019-03-29 2021-11-11 Kura Oncology, Inc. Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
CA2251716A1 (en) 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
EP0918771A4 (en) * 1996-07-15 2001-02-07 Bristol Myers Squibb Co THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
AU762423B2 (en) 1998-07-06 2003-06-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties
AU2124800A (en) * 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

Also Published As

Publication number Publication date
TR200003879T2 (tr) 2007-01-22
CN1152716C (zh) 2004-06-09
AP1599A (en) 2006-04-27
AP2001002057A0 (en) 2001-03-31
EA200100111A1 (ru) 2001-06-25
EP1094839A1 (en) 2001-05-02
CA2336624C (en) 2008-10-21
EP1094839B1 (en) 2003-05-02
AU762423B2 (en) 2003-06-26
PL193464B1 (pl) 2007-02-28
US6545020B1 (en) 2003-04-08
SK284723B6 (sk) 2005-10-06
CZ20004777A3 (en) 2001-05-16
HUP0103689A2 (hu) 2002-02-28
NO20010082L (no) 2001-01-05
EA003877B1 (ru) 2003-10-30
EE04582B1 (et) 2006-02-15
CN1311692A (zh) 2001-09-05
WO2000001411A1 (en) 2000-01-13
BR9911861A (pt) 2001-03-20
HUP0103689A3 (en) 2003-01-28
BG64941B1 (bg) 2006-10-31
CZ300968B6 (cs) 2009-09-30
MY126519A (en) 2006-10-31
KR20010052770A (ko) 2001-06-25
DE69907461D1 (de) 2003-06-05
IL140721A (en) 2008-11-26
KR100591603B1 (ko) 2006-06-20
PT1094839E (pt) 2003-09-30
DE69907461T2 (de) 2004-02-19
SI1094839T1 (en) 2003-12-31
HRP20000903A2 (en) 2001-12-31
ID26987A (id) 2001-02-22
NO328178B1 (no) 2009-12-28
PL347979A1 (en) 2002-05-06
JP4530537B2 (ja) 2010-08-25
TW586937B (en) 2004-05-11
DK1094839T3 (da) 2003-08-18
HK1034451A1 (en) 2001-10-26
AU4780599A (en) 2000-01-24
JP2002519389A (ja) 2002-07-02
SK19862000A3 (sk) 2001-12-03
ES2199579T3 (es) 2004-02-16
NO20010082D0 (no) 2001-01-05
CA2336624A1 (en) 2000-01-13
HU229076B1 (en) 2013-07-29
ATE238811T1 (de) 2003-05-15
BG105108A (en) 2001-11-30
EE200000794A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
AP2001002057A0 (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
PL330120A1 (en) Farnesilic protein transferase inhibitors
IL146094A0 (en) Diaminothiazoles and their use for inhibiting protein kinases
ZA985778B (en) Inhibitors of farnesyl protein transferase.
IL141866A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
PL348294A1 (en) Farnesyl protein transferase inhibitors
PL346934A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
HK1208456A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors 3-
EP1066286A4 (en) PROTEIN TYROSINE KINASE INHIBITORS, BASED ON IMIDAZOPYRAZINE WITH HETEROCYCLO SUBSTITUTION
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
PL343680A1 (en) Quinolones used as mrs inhibitors and bactericides
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
EP1112354A4 (en) NOVEL PROTEIN KINASE MOLECULES AND THEIR USES
HUP0202152A2 (en) Tricyclyc farnesyl protein transferase inhibitors
PL355887A1 (en) Farnesyl transferase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
IL149870A0 (en) Inhibitors of farnesyl protein transferase
ZA996763B (en) Inhibitors of protein isoprenyl transferases.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed